227 related articles for article (PubMed ID: 36705941)
1. An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.
Sun Y; Li X; Bedlack R
Expert Rev Neurother; 2023 Jan; 23(1):1-7. PubMed ID: 36705941
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis.
Paganoni S; Hendrix S; Dickson SP; Knowlton N; Macklin EA; Berry JD; Elliott MA; Maiser S; Karam C; Caress JB; Owegi MA; Quick A; Wymer J; Goutman SA; Heitzman D; Heiman-Patterson TD; Jackson CE; Quinn C; Rothstein JD; Kasarskis EJ; Katz J; Jenkins L; Ladha S; Miller TM; Scelsa SN; Vu TH; Fournier CN; Glass JD; Johnson KM; Swenson A; Goyal NA; Pattee GL; Andres PL; Babu S; Chase M; Dagostino D; Hall M; Kittle G; Eydinov M; McGovern M; Ostrow J; Pothier L; Randall R; Shefner JM; Sherman AV; St Pierre ME; Tustison E; Vigneswaran P; Walker J; Yu H; Chan J; Wittes J; Yu ZF; Cohen J; Klee J; Leslie K; Tanzi RE; Gilbert W; Yeramian PD; Schoenfeld D; Cudkowicz ME
Muscle Nerve; 2021 Jan; 63(1):31-39. PubMed ID: 33063909
[TBL] [Abstract][Full Text] [Related]
3. Analysis of sodium phenylbutyrate and taurursodiol survival effect in ALS using external controls.
Paganoni S; Quintana M; Sherman AV; Vestrucci M; Wu Y; Timmons J; Cudkowicz M;
Ann Clin Transl Neurol; 2023 Dec; 10(12):2297-2304. PubMed ID: 37807839
[TBL] [Abstract][Full Text] [Related]
4. Sodium Phenylbutyrate and Taurursodiol: A New Therapeutic Option for the Treatment of Amyotrophic Lateral Sclerosis.
Alqallaf A; Cates DW; Render KP; Patel KA
Ann Pharmacother; 2024 Feb; 58(2):165-173. PubMed ID: 37269231
[TBL] [Abstract][Full Text] [Related]
5. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.
Paganoni S; Macklin EA; Hendrix S; Berry JD; Elliott MA; Maiser S; Karam C; Caress JB; Owegi MA; Quick A; Wymer J; Goutman SA; Heitzman D; Heiman-Patterson T; Jackson CE; Quinn C; Rothstein JD; Kasarskis EJ; Katz J; Jenkins L; Ladha S; Miller TM; Scelsa SN; Vu TH; Fournier CN; Glass JD; Johnson KM; Swenson A; Goyal NA; Pattee GL; Andres PL; Babu S; Chase M; Dagostino D; Dickson SP; Ellison N; Hall M; Hendrix K; Kittle G; McGovern M; Ostrow J; Pothier L; Randall R; Shefner JM; Sherman AV; Tustison E; Vigneswaran P; Walker J; Yu H; Chan J; Wittes J; Cohen J; Klee J; Leslie K; Tanzi RE; Gilbert W; Yeramian PD; Schoenfeld D; Cudkowicz ME
N Engl J Med; 2020 Sep; 383(10):919-930. PubMed ID: 32877582
[TBL] [Abstract][Full Text] [Related]
6. Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes.
Paganoni S; Watkins C; Cawson M; Hendrix S; Dickson SP; Knowlton N; Timmons J; Manuel M; Cudkowicz M
Muscle Nerve; 2022 Aug; 66(2):136-141. PubMed ID: 35508892
[TBL] [Abstract][Full Text] [Related]
7. Sodium phenylbutyrate-taurursodiol access, adherence and adverse event in patients with amyotrophic lateral sclerosis: Experience at one center in the United States.
Mamarabadi M; Fafoutis E; Geronimo A; Walsh S; Simmons Z
Muscle Nerve; 2024 Aug; 70(2):204-209. PubMed ID: 38828849
[TBL] [Abstract][Full Text] [Related]
8. Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial.
Paganoni S; Hendrix S; Dickson SP; Knowlton N; Berry JD; Elliott MA; Maiser S; Karam C; Caress JB; Owegi MA; Quick A; Wymer J; Goutman SA; Heitzman D; Heiman-Patterson TD; Jackson C; Quinn C; Rothstein JD; Kasarskis EJ; Katz J; Jenkins L; Ladha SS; Miller TM; Scelsa SN; Vu TH; Fournier C; Johnson KM; Swenson A; Goyal N; Pattee GL; Babu S; Chase M; Dagostino D; Hall M; Kittle G; Eydinov M; Ostrow J; Pothier L; Randall R; Shefner JM; Sherman AV; Tustison E; Vigneswaran P; Yu H; Cohen J; Klee J; Tanzi R; Gilbert W; Yeramian P; Cudkowicz M
J Neurol Neurosurg Psychiatry; 2022 May; 93(8):871-5. PubMed ID: 35577511
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents.
Johnson SA; Fang T; De Marchi F; Neel D; Van Weehaeghe D; Berry JD; Paganoni S
Drugs; 2022 Sep; 82(13):1367-1388. PubMed ID: 36121612
[TBL] [Abstract][Full Text] [Related]
10. A single ALS center experience with clinical use of sodium phenylbutyrate-taurursodiol.
Quinn C; Baer M; Amado DA; Kelley M; Elman L
Muscle Nerve; 2024 Jul; 70(1):148-151. PubMed ID: 38670927
[TBL] [Abstract][Full Text] [Related]
11. Effect of sodium phenylbutyrate and taurursodiol on plasma concentrations of neuroinflammatory biomarkers in amyotrophic lateral sclerosis: results from the CENTAUR trial.
Bowser R; An J; Mehta L; Chen J; Timmons J; Cudkowicz M; Paganoni S
J Neurol Neurosurg Psychiatry; 2024 Jun; 95(7):605-608. PubMed ID: 38050066
[TBL] [Abstract][Full Text] [Related]
12. Managed care considerations to improve health care utilization for patients with ALS.
Wong W
Am J Manag Care; 2023 Jun; 29(7 Suppl):S120-S126. PubMed ID: 37433093
[TBL] [Abstract][Full Text] [Related]
13. Optimizing pharmacologic treatment for ALS to improve outcomes and quality of life.
Lynch K
Am J Manag Care; 2023 Jun; 29(7 Suppl):S112-S119. PubMed ID: 37433092
[TBL] [Abstract][Full Text] [Related]
14. CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS).
Bireley JD; Morren JA
Expert Opin Investig Drugs; 2023; 32(8):677-683. PubMed ID: 37642362
[TBL] [Abstract][Full Text] [Related]
15. Study protocol of RESCUE-ALS: A Phase 2,
Vucic S; Kiernan MC; Menon P; Huynh W; Rynders A; Ho KS; Glanzman R; Hotchkin MT
BMJ Open; 2021 Jan; 11(1):e041479. PubMed ID: 33431491
[TBL] [Abstract][Full Text] [Related]
16. Effects of PB-TURSO on the transcriptional and metabolic landscape of sporadic ALS fibroblasts.
Fels JA; Dash J; Leslie K; Manfredi G; Kawamata H
Ann Clin Transl Neurol; 2022 Oct; 9(10):1551-1564. PubMed ID: 36083004
[TBL] [Abstract][Full Text] [Related]
17. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
[TBL] [Abstract][Full Text] [Related]
18. Small molecules targeting different cellular pathologies for the treatment of amyotrophic lateral sclerosis.
Elmansy MF; Reidl CT; Rahaman M; Özdinler PH; Silverman RB
Med Res Rev; 2023 Nov; 43(6):2260-2302. PubMed ID: 37243319
[TBL] [Abstract][Full Text] [Related]
19. Sodium Phenylbutyrate and Tauroursodeoxycholic Acid: A Story of Hope Turned to Disappointment in Amyotrophic Lateral Sclerosis Treatment.
Ketabforoush A; Faghihi F; Azedi F; Ariaei A; Habibi MA; Khalili M; Ashtiani BH; Joghataei MT; Arnold WD
Clin Drug Investig; 2024 Jun; ():. PubMed ID: 38909349
[TBL] [Abstract][Full Text] [Related]
20. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
